We found that gefitinib significantly increased the immune response of anti-PD-1 antibody by reducing the interaction between PD-L1 and PD-1 (Fig. 5c), by enhancing IL-2 expression in T cells (Fig. 5d), and by elevating T-cell-mediated tumour cell killing (Fig. 5e). The gene discussed is IL2; the disease is neoplasm.